New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

Being overweight raises your risk of thyroid cancer ... One study reported that the incidence of thyroid cancer in semaglutide-treated patients was less than 1%. As of now, the FDA warning ...

Ozempic (semaglutide) and Mounjaro (tirzepatide ... doctor to see if these warnings apply to you. Boxed warning: Risk of thyroid cancer Ozempic and Mounjaro both have a boxed warning for the ...

Semaglutide also delays gastric emptying ... but the label indicates thyroid cancer risk. Contraindications include a personal or family history of medullary thyroid carcinoma (MTC) or multiple ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk ... semaglutide injection 2.4 mg contains a Boxed Warning for possible thyroid tumors, including cancer ...

The large-scale study focused on use of semaglutide and non-GLP-1 RAs. An increased risk for nonarteritic anterior ischemic optic neuropathy with semaglutide was seen at 2, 3 and 4 years from the ...